1 Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone : Reduction of disease activity with oral risedronate. Bone 1998 ; 22 : 51-5.
2 Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A prospective, multicenter, randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999 (in press).
3 Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in pa-tients with multiple myeloma. Bo-ne 1994 ; 15 : 41-9.
4 Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A two-year phase II study with one-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporosis Int 1997 ; 7 : 488-95.
5 Mortensen L, Charles P, Bekker PJ, DiGennaro J, Johnston Jr CC. Risedronate increases bone mass in an early postmenopausal population : Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998 ; 83 : 396-402.
6 Hooper M, Ebeling P, Roberts A, et al. Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int 1999 ; 64 (Suppl. 1) : S69.
7 Fogelman I, Ribot C, Smith R, et al. Risedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass. Calcif Tissue Int 1999 ; 64 (Suppl. 1) : S69.
8 Eastell R, Minne H, Sorensen O, et al. Risedronate reduces fracture risk in women with established postmenopausl osteoporosis. Calcif Tissue Int 1999 ; 64 (Suppl. 1) : S43.
9 Watts N, Hangartner T, Chesnut C, et al. Risedronate prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 1999 ; 64 (Suppl. 1) : S42.